Background

Acute traumatic coagulopathy (ATC) has been linked to an increase in activated protein C (aPC) from 40 pM in healthy individuals to 175 pM. aPC exerts its activity primarily through cleavage of active coagulation factor Va (fVa). Platelets reportedly possess fVa which is more resistant to aPC cleavage than plasma fVa; this work examines the hypothesis that normal platelets are sufficient to maintain coagulation in the presence of elevated aPC.

Methods: Coagulation responses of normal plasma, fV deficient plasma (fVdp), and isolated normal platelets in fVdp were conducted: prothrombin (PT) tests, turbidimetry, and thromboelastography (TEG), including the dose response of aPC on the samples.

Results: PT and turbidimetric assays demonstrate that normal plasma is resistant to aPC at doses much higher than those found in ATC. Additionally, an average physiological number of washed normal platelets (200,000 platelets/mm³) was sufficient to eliminate the anti-coagulant effects of aPC up to 10 nM, nearly two orders of magnitude above the ATC concentration and even the steady-state pharmacological concentration of human recombinant aPC, as measured by TEG. aPC also demonstrated no significant effect on clot lysis in normal plasma samples with or without platelets.

Conclusions: Although platelet fVa shows slightly superior resistance to aPC's effects compared to plasma fVa in static models, neither fVa is sufficiently cleaved in simulations of ATC or pharmacologically-delivered aPC to diminish coagulation parameters. aPC is a likely a correlating indicator of ATC or may play a cooperative role with other activity altering products generated in ATC.

Abstract

Background: Acute traumatic coagulopathy (ATC) has been linked to an increase in activated protein C (aPC) from 40 pM in healthy individuals to 175 pM. aPC exerts its activity primarily through cleavage of active coagulation factor Va (fVa). Platelets reportedly possess fVa which is more resistant to aPC cleavage than plasma fVa; this work examines the hypothesis that normal platelets are sufficient to maintain coagulation in the presence of elevated aPC.

Methods: Coagulation responses of normal plasma, fV deficient plasma (fVdp), and isolated normal platelets in fVdp were conducted: prothrombin (PT) tests, turbidimetry, and thromboelastography (TEG), including the dose response of aPC on the samples.

Results: PT and turbidimetric assays demonstrate that normal plasma is resistant to aPC at doses much higher than those found in ATC. Additionally, an average physiological number of washed normal platelets (200,000 platelets/mm³) was sufficient to eliminate the anti-coagulant effects of aPC up to 10 nM, nearly two orders of magnitude above the ATC concentration and even the steady-state pharmacological concentration of human recombinant aPC, as measured by TEG. aPC also demonstrated no significant effect on clot lysis in normal plasma samples with or without platelets.

Conclusions: Although platelet fVa shows slightly superior resistance to aPC's effects compared to plasma fVa in static models, neither fVa is sufficiently cleaved in simulations of ATC or pharmacologically-delivered aPC to diminish coagulation parameters. aPC is a likely a correlating indicator of ATC or may play a cooperative role with other activity altering products generated in ATC.
with damage to large microvascular beds remains to be determined.

High concentrations of aPC are thought to facilitate fibrinolysis, possibly through binding plasminogen activator inhibitor-1 (PAI-1) [16,17]. This is further corroborated by a correlation between decreasing protein C and PAI-1 with increasing tissue plasminogen activator (t-PA) and t-dimer [8,18]. However, the profibrinolytic properties of aPC are dependent on its downstream effects on thrombin-activatable fibrinolysis inhibitor (TAFI); inactivation of IVa reduces fIIa production which reduces TAFI activation [19]. In trauma, activated platelets release Platelet Factor 4 (PF4), which acts as a soluble cofactor promoting aPC generation by the fIIa-TM complex while simultaneously inhibiting the activation of TAFI by fIIa-TM [20]. This complexity of mechanisms suggests that the interaction of aPC and PAI-1 may actually be insignificant since the reduction in fIIa production by aPC could lead to a delay in fibrinolysis [21].

Since ATC is characterized by PC activation, depletion of IV/ fVIII, and possible fibrinolytic effects from aPC neutralization of PAI-1, it is posited that a large-scale activation of PC in massive trauma is directly responsible for the poor outcomes associated with ATC. Circulating aPC levels have been estimated at about 40 pM in healthy individuals [22]. It has been suggested that ATC is induced by aPC levels near 10 ng/mL (~175 pM), reflecting activation of approximately 0.2% of the total average circulating protein C (3750 ng/mL; ~65.8 nM) [10]. Drotrecogin alfa (activated) (DrotAA) is recombinant human aPC previously marketed for severe sepsis under the brand name Xigris (Eli Lilly, Indianapolis, IN); the median steady-state concentration of DrotAA following an infusion of 12–30 µg/kg/hr is 790 pM, dissipating below 10 ng/mL within two hours [23]. Both 175 pM and 790 pM are considered anti-thrombotic within their clinical contexts, sufficient to reduce plasma IV levels [10,24,25].

IV exists in two pools distinguished by differences in structure, function, and susceptibility to inactivation: the platelet IV fraction (~20%) has been established as being refractory to aPC cleavage compared to the plasma fraction (~90%) [26–29].

Previous studies have shown that hemostatic thrombin generation can be produced by introducing platelets in patients suffering from IV-deficiency or in plasma treated to be IV-deficient [29]. We hypothesized that a physiologically normal concentration of healthy platelets would possess IV capable of resisting the anti-coagulant effects of aPC at the reported ATC-inducing concentration. To test this hypothesis, we investigated the concentration of aPC required to induce significant delays in clot time, decrease clot strength, or induce fibrinolysis as described in ATC, as well as the number of platelets necessary to correct aPC-perturbed coagulation parameters. The results indicate that the concentration of aPC required to induce an acute coagulopathy in an otherwise healthy patient’s plasma is well beyond reported pathophysiologic levels. In platelets especially, IV is resistant to moderately high aPC in clinically relevant static or low-shear models such as thromboelastography.

**Methods**

**Ethics Statement**

This study was conducted under a protocol reviewed and approved by the San Antonio Military Medical Center Institutional Review Board, and in accordance with good clinical practices. Written informed consent was obtained from blood donors.

**Blood and Plasma Preparation**

De-identified fresh whole blood from healthy donors (50 mL) was collected in 4.5 mL BD Vacutainer tubes (10.9 mM buffered sodium citrate; Becton-Dickinson, Franklin Lakes, NJ); each sample was collected from a new donor and processed immediately.

Plasma samples were prepared through a series of centrifugation steps: 200-g for 10 min with minimal braking separated platelet-rich plasma (PRP) which was collected and stored at 22 °C; additional centrifugation of the sample at 2,000-g for 10 min isolated platelet-poor plasma (PPP). PPP was additionally centrifuged at 10,000-g for 4 min to generate platelet-free plasma (PFP) and kept on ice until use.

Frozen citrated IV immunodepleted plasma (IVdp; Haematologic Technologies, Essex Junction, VT) was rapidly thawed at a 37 °C water bath immediately prior to use. Per the manufacturer, this lot of plasma (BB0926) has a prothrombin time (PT) of 53.7 s; activated partial thromboplastin time (APTT) of 110.9 s, IV<1% normal, and other coagulation factors within normal ranges. Frozen citrated IVIII chemically depleted plasma (IVIIIdp; Haematologic Technologies) was handled in the same manner; this lot of plasma (DD0220B) has a PT of 12.1 s, an APTT of 91.8 s, IVIII<1% normal, and other coagulation factors in their normal ranges.

Corn trypsin inhibitor (CTI; 20 µg/mL; Haematologic Technologies) was added to all samples to assure contact pathway blockade for 1 hour. The lipidated recombinant tissue factor Innovin (Dade-Behring, Marburg, Germany) was used to initiate clotting at a 1:5000 dilution. Citrated plasma was recalcified immediately prior to experiments with 15 nM CaCl₂ (Sigma-Aldrich, St. Louis, MO).

**PT/INR Analysis**

The STA-R Evolution (Diagnostica-Stago, Parsippany, NJ) was used to collect PT data. Briefly, 100 µL STA Neoplastine CI Plus 10 reagent (freeze-dried thromboplastin from rabbit containing calcium) was prepared according to manufacturer’s instructions and mixed with 50 µL plasma (pre-incubated at 37 °C). The Mean Normal PT is listed as 15.5 s for this device, and INR is calculated by the formula INR = (Sample PT/ Mean Normal PT) [30], where ISI is the International Sensitivity Index, given as 1.21 for these reagents.

**Turbidimetric Assays**

The Spectramax M5e plate reader spectrophotometer (Molecular Devices, Sunnyvale, CA) was used to collect turbidimetric absorbance measurements which are correlated with fibrin network formation. The spectrophotometer was run in kinetic absorbance mode (405 nm) for 90 min with 20 s intervals at 37 °C. Total volume per well was 100 µL. Assays were conducted in 96-well flat clear bottom polystyrene non-treated microplates (Costar 3615, Corning, Tewksbury, MA). Results were exported from SoftMax Pro 5.4.5 (Molecular Devices) for analysis.

The effects of purified aPC (Lot CC0118, Haematologic Technologies) on clot time in plasma were examined by performing a serial dilution of aPC concentrations from 0.001–100 nM, with 100 nM being ~50% above the theoretical average maximum amount of aPC that can exist systemically (~63.8 nM). This protein was used in all aPC-inclusive assays and has been demonstrated to have full physiologic function [30–34].

aPC concentrations were incubated with plasma for 3 min at room temperature. Innovin was added to plasma immediately before distribution to the 96-well plate (preloaded with CaCl₂). The ability of recombinant human soluble EPCR (Novoprotein,
Isolated Platelets
Platelets were washed and isolated from PRP similarly to the procedure of Mustard et al [35]. Briefly, 0.02 U/mL apyrase (Sigma-Aldrich) and 1.0 μM prostaglandin I2 (PGI2; MP Biomedicals, Solon, OH) were added to PRP to prevent platelet activation. PRP was centrifuged at 1,000-g for 10 min at room temperature without braking. Following plasma aspiration, the platelet pellet was gently resuspended with 10 mL of modified Tyrode’s albumin buffer (MTAB: 137 mM NaCl, 2.68 mM KCl, 11.9 mM NaHCO3, 0.43 mM Na2HPO4, 1.0 mM MgCl2, 5 mM HEPES, 0.35% BSA, 5.55 mM D(+)-Glucose). Additional apyrase (0.01 U/mL) and PGI2 (0.5 μM) were added; the platelets were centrifuged again at 1,000-g for 10 min at room temperature without braking, and the pellet was resuspended at high concentration in 300 μL of modified Tyrode’s albumin buffer. Platelets were counted using a Coulter Ac-T diff2 hematology analyzer (Beckman Coulter, Inc., Indianapolis, IN) and adjusted to the desired concentration by the addition of fVdp prior to use.

Thromboelastography
Thromboelastographic (TEG) assays were conducted with the Haemoscope TEG 5000 Coagulation Analyzer (Haemoscope Corp., Niles, IL). The clinical availability and common usage of this device provides an alternative measurement of blood clotting to the turbidimetric assay, particularly in samples containing red blood cells which interfere with the opacity.

The effects of aPC dose were determined on fVdp and normal plasma samples with or without washed platelets, using Innovin and CaCl2 to activate coagulation. The total volume per sample was 300 μL; samples were run for 3 h.

fVIII activity
The dose-response of fVIII activity to aPC was evaluated using the STA - Deficient VIII assay on the STA-R Evolution per manufacturer’s instructions.

Statistics
For all experiments, n≥3. Variance component estimates (JMP software, SAS Institute, Cary, NC) were used to demonstrate that sample-to-sample random effects comprised an insignificant portion of the observed variance. Prism 5 (GraphPad Software, La Jolla, CA) was used to generate graphs and perform two-way analysis of variance with repeated measures and pair-wise comparison Bonferroni posttests.

Results
Nanomolar aPC Is Required to Prolong PT/INR
PT measurements in fVdp are delayed compared to normal PFP [43.9 s in fVdp control versus 13.5 s in PFP control, Figure 1]. The addition of a 2 nM concentration of IV protein to fVdp had a slightly restorative effect (PT = 31.2 s), and 20 nM IV reduced PT to 19.6 s in control fVdp samples.

A dose-response analysis of exogenous aPC illustrates that normal and even IV-deficient plasmas are resistant to aPC effects on PT at levels below 10 nM. In normal PFP, there is no statistically significant increase in PT until the aPC concentration exceeds 33 nM. In the fVdp samples, the effects of aPC are noticeable above 3.3 nM. The addition of 2 nM IV slightly reduces the effect of increasing aPC from 3.3 nM to 10 nM, and a 20 nM IV supplementation is resistant to aPC-induced PT prolongation until the concentration of aPC is greater than 10 nM. Calculated INR values ranged from 1.0 (PFP with aPC≤1 nM) to 8.3 (fVdp with 100 nM aPC).

Nanomolar aPC Is Required to Delay Fibrin Crosslinking
Optical density of plasma increases with fibrin crosslinking [36]. A turbidimetric assay was used to observe the effects of aPC on fibrin crosslinking following activation with Innovin (Figure 2). aPC had no significant effect on fVdp fibrin crosslinking (Figure 2A) at a dose of 1 nM or lower (initiation of clotting occurred at approximately 19 min), although as in the PT study, clotting was inherently delayed in fVdp (note x-axis range differences between 2A/2B). In fVdp, 3.3 nM aPC delayed crosslinking to approximately 24 min (p<0.05); 10 nM aPC or higher prevented crosslinking within the 90 minute measurement window (p<0.001). For PFP (Figure 2B), there was a significant delay in fibrin crosslinking starting at 10 nM aPC (p<0.05).

Platelet or Plasma-Derived fV Restores Coagulation Parameters in fVdp
The effect of IV on the coagulation response profile in TEG (Figure 3) was determined by adding IV to fVdp over concentrations from 1–40 nM (average normal is 20 nM) [37]. R-time (clot initiation time, Figure 3A) decreases as IV increases from 1–10 nM and then stabilizes at a minimum time of 4 min. The alpha-angle (clot formation rate, Figure 3B) follows an inverse pattern, increasing as IV increases from 1–10 nM, to a plateau of approximately 60°. The G-value (maximum shear elastic modulus, strength of clot, Figure 3C) is unaffected by IV levels.

Similarly to the direct addition of IV protein, increasing platelet counts from 10,000–400,000 platelets/mm3 decreased TEG R-time of fVdp, although increasing above 200,000 platelets/mm3 resulted in minimal improvements to clot time, rate of clotting, or clot strength (Figure 4). In normal PFP, clotting time did not change significantly across the range of platelet counts (Figure 4A).
Comparing an equivalent number of platelets suspended in either fVdp or normal PFP, significant differences in clot time are seen only at counts ≤200,000 platelets/mm³. The alpha-angle (Figure 4B) and G-value (Figure 4C) of equivalent platelet concentrations in fVdp and PFP were statistically indistinguishable.

Washed, non-activated platelets at a concentration of 200,000 platelets/mm³ in fVdp eliminated the anti-coagulant effect of aPC up to 10 nM, greatly above systemic concentrations measured in either ATC or DrotAA treatment (Figure 5A). At 33 nM aPC dose, the mean clotting time increased to 21.5 min (p<0.05), and at 100 nM aPC the clot time was extended to 56.1 min (p<0.001).

Significant differences in alpha-angle (Figure 5B) were not observed until 33 nM aPC when it changed from an average 76.8° at 0.001–10 nM aPC to 46.8° at 33 nM aPC and 13.6° at 100 nM aPC (p<0.001 for both compared to lower doses).

Similarly, G-value (Figure 5C) was nearly unaffected by even very high aPC doses. Clot strength was significantly decreased only at 100 nM aPC (p<0.001).

The variance in coagulation parameters found at high aPC concentrations (Figure 5) indicates that individual patients have different thresholds at which they are susceptible to aPC effects, likely due to variability in individual fV availability or other aspects of coagulation factor structure and function.

**aPC and tPA Have No Synergistic Effect on Clot Lysis In Vitro**

Activation of PC in ATC may derepress fibrinolysis through aPC degradation of plasminogen activator inhibitor (PAI-1). We examined fibrinolysis in the presence or absence of both aPC and tPA. tPA is released by endothelium and activates plasminogen to plasmin. Plasmin then cleaves crosslinked fibrin, reducing clot size and stability. The pro-fibrinolytic effects of aPC and possible synergy with tPA were evaluated by adding doses corresponding to the proposed ATC level of aPC (175 pM) and the pharmacologic steady-state concentration of DrotAA (750 pM) to normal PFP and PRP (normalized to 200,000 platelets/mm³) in combination with doses of tPA known to produce specific fibrinolytic effects [0, 1, 1.5, and 2 nM] [38].

Increasing tPA resulted in the expected increase in clot lysis in both plasmas, but increasing aPC had no synergistic effect with tPA; pair-wise comparisons indicated no significant difference in clot lysis between APC concentrations for a given amount of tPA (Figure 6).

**Effects of aPC on Phospholipid Acceleration of Fibrin Formation**

Because the phospholipid layer plays an important role in coagulation (of central importance in the activation of IX and thrombin), be it from the platelet, the endothelium, or the microvesicles which exist normally and are elevated in trauma and disease states, it is of some interest to evaluate how the dose-response of phospholipids (PL) modulates the anticoagulant effects of aPC. As an aside, PL is also required for the activation of PC. We examined the effects of PL on coagulation in the presence of aPC by performing a dual dose-response experiment on normal PFP samples. It has previously been shown that thrombin generation rates of platelets within the physiological range correspond to a dose of 1–2 µM PL (a mixture of 25:75 PS:PC was used in that study) [39].

Using the turbidimetric assay, fibrin crosslinking was measured over a range of 0–5 µM PL (a mixture of 28:42:30 PS:PC:SM) and 0.01–100 nM aPC (Figure 7). As expected, increasing the amount of available PL reduced the time for the initiation of fibrin crosslinking and increased the rate of fibrin crosslinking but had no effect on the maximum absorbance for low concentrations of aPC (which again had negligible effects below 1 nM). At 3.3 nM aPC, a delay in fibrin crosslinking is observed regardless of PL concentration; at 10 and 33 nM concentrations of aPC, PL no longer provides a procoagulant effect. No crosslinking was observed at 100 nM aPC.

**aPC Anticoagulant Activity Is Not Affected by sEPCR Alone**

Brief studies were conducted to evaluate the modulation of aPC’s anticoagulant activity by EPCR. A commercially available soluble recombinant human EPCR protein was evaluated in the same dual dose response turbidimetric assay (with EPCR instead of PL). Soluble EPCR (sEPCR) exists at a physiological concentration of 2.5 nM in normal individuals and can be elevated as much as five-fold in inflammatory conditions such as systemic lupus erythematosus [40]. However, over the range of 0–200 nM sEPCR, no effect on fibrin crosslinking was observed beyond that generated by aPC alone (data not shown). sEPCR has previously been shown to inhibit the anticoagulant activity of aPC.
but only in the presence of PL (although not through direct binding to PL vesicles) [41].

Nanomolar aPC is Required to Degrade fVIII Activity

The degradation of fVIII by aPC has a negligible effect on thrombin generation particularly compared to those effects seen through aPC lysis of fVa [12]. For purposes of hemostasis maintenance, fVIII is protected from proteolysis following synthesis through formation of a complex with von Willebrand Factor (VWF), and conversely fVIII has other inactivation and clearance mechanisms primarily found in the liver [42,43].

The activity of fVIII was examined for the same aPC dose-response. In fresh PFP, no change in fVIII activity by aPC was observed until a dose >10 nM (p<0.001) (Figure 8). Studies on fVdp showed a similar trend (p<0.05 when comparing 3.3 nM and 100 nM aPC); fVIIIdp was used as a negative control and showed <1% activity throughout.

Discussion

fVa acts as a cofactor of fXa, increasing the rate of prothrombin activation over 600-fold compared with phospholipid-associated fXa alone [44]. Although IV^{-} is embryonic lethal in mice [45],
Trace amounts of fV found in patients with severe fV-deficiency appear to be sufficient to allow adequate hemostasis [29]. This is partially due to the low level of tissue factor pathway inhibitor in these patients which may act as a compensatory mechanism by improving thrombin generation [46]. However, adequate hemostasis in individuals with normal to low levels of platelet fV and only traces of plasma fV reflects the importance of platelet function and the platelet fV pool. Co-localization of fVa and phospholipid as a result of platelet deposition accelerates thrombin generation and fibrin formation/crosslinking at sites of injury while maintaining flow within vessels [46].

The present results and others [26–28] illustrate the relative importance of the platelet fV fraction, although nanomolar concentrations of aPC are required to significantly affect clotting in both normal and fV-deficient plasmas. At 10 ng/mL (175 pM), the concentration of aPC associated with ATC [10], no alterations are observed in PT, clotting time, rate of clot formation, strength of clot, or any other metrics obtainable by either turbidimetry or thromboelastography. As shown in other models, aPC did not induce fibrinolysis except at significantly higher doses than those obtained by administration of DrotAA [47,48], and no synergy in clot lysis is observed with the addition of aPC to tPA at these relevant concentrations. This may be explained by the complexity of aPC interactions with the fibrinolytic system: on one hand, aPC has been shown to decrease PAI-1 activity [49] (or vice versa [50]); on the other hand, potential reductions in thrombin generation may reduce thrombin-dependent inactivation of PAI-1 [21].

Microvesicles are found in healthy individuals and have been shown to generate small amounts of thrombin which could lead to activation of PC [51], corresponding to the expected homeostatic function of aPC in the healthy individual as a negative feedback regulator of coagulation. In a trauma or sepsis scenario, these microvesicles may have a different function; large amounts of aPC...
are capable of inducing the formation of microvesicles featuring associated EPCR as shown through in vitro cell culture studies (aPC dose of 6.25–100 nM) [52] and in septic patients undergoing DrotAA treatment (standard infusion of 24 µg/kg/hr) [53]. As PC associates with these EPCR-bearing microvesicles it can be activated and perform its anticoagulant proteolytic functions on fVa and fVIIIa. However, the brief studies conducted in this report with the individual components of these aPC-EPCR-microvesicles (using soluble EPCR and a PL emulsion) did not elucidate the mechanisms by which differences in the efficiency of soluble aPC or EPCR-microvesicle bound aPC might be observed. The effects of the combination of sEPCR and PL vesicles were not studied, as it has already been demonstrated that the sEPCR-aPC complex does not bind to PL vesicles [41].

These results confirm and expand those from previous studies examining the anticoagulant effects of aPC in purified systems. Efficacy of aPC at nanomolar concentrations has been shown to be reduced in the presence of platelets but not phospholipid alone [54], and aPC is ineffective at inhibiting both platelet adhesion and fibrin formation in blood flow models except at extreme

Figure 7. aPC concentrations below 10 nM have no significant effect on PL acceleration of clotting in PFP. In the turbidimetric assay, fibrin crosslinking corresponds to an increase in absorbance at 405 nm wavelength. Increasing the amount of available PL reduced the time for the initiation of fibrin crosslinking and increased the rate of fibrin crosslinking but had no effect on the maximum fibrin crosslinking as observed for all concentrations of aPC below 10 nM. aPC concentrations above 10 nM did not display any fibrin crosslinking within the first 30 min, and PL no longer provides any procoagulant benefit. Curves are averages of three independent plasma samples.

doi:10.1371/journal.pone.0099181.g007
superphysiological concentrations (16 μg/ml; 285 nM) [55]. aPC has also been shown to be incapable of acding activation of platelets by thrombin-receptor-agonist-peptide-6 (TRAP) or ADP at DrotAA pharmacological doses (45 ng/ml; 790 pM) and even five-fold higher concentrations [56], while activation of platelets by arachidonic acid, ADP, and collagen was unaltered even at very high aPC doses (10 μg/ml; 178 nM), although that extreme concentration did inhibit activation of platelets by recombinant tissue factor [57]. It has been hypothesized that timing is key; if sufficient aPC is allowed to interact with FVa and/or FVIIIa prior to their involvement in prothrombinase/tenase complex activity, its anticoagulant function may be enhanced as these complexes provide some protection from aPC proteolysis [58–60]. What bearing this has in vivo in either on healthy or trauma-altered hemostasis remains unclear.

The results presented here should be interpreted with caution given the limitations inherent in characterizing complex and dynamic physiology with ex vivo coagulation tests. Nevertheless, the modest increase in aPC levels observed in patients with ATC is unlikely to be the main cause of this coagulopathy. Our results are in line with those found by Gruber et al. which demonstrated in baboon studies that high plasma levels (3.6 nM) following exogenously delivered aPC decreased thrombosis (measured via APTT and fibrin deposition) and platelet aggregation [48]. However, studies by Gruber et al. further showed no hemostatic alteration (measured by bleeding times) and therefore suggest concentrations of aPC investigated in our experiments likely fall short of hemostatic perturbation values in vivo. Furthermore, the characterization of ATC as a “hypocoagulable” state induced by aPC obscures the fact that activation of PC requires prior robust thrombin generation [11,61]. ATC is characterized by exaggerated activation of thrombin and eventual depletion over time of multiple coagulation factors, platelets and inhibitors through transition to Coagulopathy of Trauma [3]. It occurs in the setting of shock where loss of hydrostatic pressure alters the net Starling fluid flux which drives progressive autodilution of blood [62–64]. Detection of increased aPC may reflect the final stages of a robust physiologic response to a massive hemostatic challenge rather than a primary anticoagulant response. Regardless, our results indicate that platelets provide adequate FV to overcome the effects of very high aPC concentrations, even in the absence of plasma FV. This finding may explain part of the apparent benefit to early platelet transfusion in trauma patients [65,66]. However, these present results also indicate that plasma FV is significantly resistant to aPC degradation even at pharmacological levels which indicates that the cause of ATC is more complicated than simply exuberant activation of protein C. Taken together, these data illustrate that the function of aPC is to delay clotting by dampening thrombin generation in a non-linear, protein S-dependent fashion [67], which in a healthy vasculature must be sufficient to mitigate thrombotic tendencies. aPC is not a true anticoagulant in the sense that heparin or directed thrombin inhibitors are; even in a closed system, it does not prevent or weaken clotting except at extremely high concentrations.

Critically, therapeutic approaches designed to prevent aPC generation or inhibit aPC efficacy may be counter-productive; the anti-inflammatory and anti- apoptotic cytoprotective effects [68,69] of aPC may constitute an adaptive response to tissue injury. Additionally, protein C inhibitor (PCI) and 9α anti-trypsin (9αAT) which readily bind and inhibit aPC activity [70] have not been evaluated for changes in trauma patient blood samples and may play a significant role in mediating elevated aPC effects.

Acknowledgments

The authors would like to thank Armando C. Rodriguez and Melanie V. Valenciana for their technical assistance and Ron S. Bryant, Yong H. Lee, and Dale M. Cnaya for their generous assistance with phlebotomy and operation of the STAR-Evolution.

The opinions or assertions contained herein are the private views of the author and are not to be construed as official or as reflecting the views of the Department of the Army or the Department of Defense.

This study was conducted under a protocol reviewed and approved by the San Antonio Military Medical Center Institutional Review Board, and in accordance with good clinical practices.

Author Contributions

Conceived and designed the experiments: MAM JEC APC. Performed the experiments: MAM. Analyzed the data: MAM. Wrote the paper: MAM JEC APC.

References

1. Gando S, Wada H, Thachil J (2013) Differentiating disseminated intravascular coagulation (DIC) with the fibrinolytic phenotype from coagulopathy of trauma and acute coagulopathy of trauma-shock (COT/ACOTS): J Thromb Haemost 11: 826–835.
2. Bouillon B, Brohi K, Hess JR, Holcomb JB, Parr MJ, et al. (2010) Educational Initiative on Critical Bleeding in Trauma: Chicago, July 11–13, 2008. J Trauma 68: 225–230.
3. Brohi K, Cohen MJ, Davenport RA (2007) Acute coagulopathy of trauma: mechanism, identification and effect.Curr Opin Crit Care 13: 680–685.
4. Hess JR, Brohi K, Dutton RP, Hauser CJ, Holcomb JB, et al. (2008) The coagulopathy of trauma: a review of mechanisms. J Trauma 65: 740–754.
5. Pulcode HF, Aden JR, Mora AG, Borgman MA, Spindel PC, et al. (2012) Ten-year analysis of transfusion in Operation Iraqi Freedom and Operation Enduring Freedom: increased plasma and platelet use correlates with improved survival. J Trauma Acute Care Surg 73: 5445–5452.
6. Cohen MJ, Bir N, Rahn P, Dotson R, Brohi K, et al. (2009) Protein C depletion early after trauma increases the risk of ventilator-associated pneumonia. J Trauma 67: 1176–1181.
7. Brohi K, Singh J, Heron M, Coats T (2003) Acute traumatic coagulopathy. J Trauma 54: 1127–1130.
8. Brohi K, Cohen MJ, Ganter MF, Schultz MJ, Levi M, et al. (2008) Acute coagulopathy of trauma: Hyperfusion induces systemic anticoagulation and hyperfibrinolysis. J Trauma 64: 1211–1217.
9. Chesbrough BB, Rahn P, Carles M, Esmon CT, Xu J, et al. (2009) Increase in activated protein C mediates acute traumatic coagulopathy in mice. Shock 32: 659–665.
10. Cohen MJ, Call M, Nelson M, Calif T, Eason CT, et al. (2012) Clinical role of activated protein C in early coagulopathy and later organ failure, infection and death in trauma patients. Ann Surg 255: 379–385.

11. Stearns-Kurosawa DJ, Kurosawa S, Mollica JS, Ferrell GL, Eason CT (1996) Mononuclear leukocytes augment thrombin generation: a role for activated protein C. Nature 384: 66–68.

12. van ’t Veer C, Golden NJ, Kalafatis M, Mann KG (1997) Down-regulation of prothrombinase by activated protein C. BMC Syst Biol 6: 45.

13. Lenting PJ, van Mook JA, Mertens K (1998) The life cycle of coagulation factor Va. J Biol Chem 273: 2719–2727.

14. Lenting PJ, van Mook JA, Mertens K (2000) Mechanisms by which soluble endothelial cell protein C receptor modulates protein C activation and activated protein C function. J Biol Chem 275: 5447–5452.

15. Kim PY, Nesheim ME (2010) Inversion of activated protein C function. J Biol Chem 275: 5447–5452.

16. Taylor FB, Jr., Peer GT, Lockhart MS, Fritsch P, et al. (2001) Endothelial cell protein C receptor augments protein C activation by suppressing the thrombin-dependent inactivation of PAR-1. J Thromb Haemost 1: 2561–2620.

17. Taylor FB, Jr., Lockhart MS (1995) The clinical and functional relevance of microparticles induced by activated protein C. J Mol Cell Cardiol 27: 502–510.

18. Taylor FB, Jr., Peer GT, Lockhart MS, Fritsch P, et al. (2001) Endothelial cell protein C receptor augments protein C activation by suppressing the thrombin-dependent inactivation of PAR-1. J Thromb Haemost 1: 2561–2620.

19. Camire RM, Kalafatis M, Cushman M, Tracy RP, Mann KG, et al. (1995) Plasma factor Va kinetics in vivo. Blood 85: 2093–2100.

20. Camire RM, Kalafatis M, Cushman M, Tracy RP, Mann KG, et al. (1995) Plasma factor Va kinetics in vivo. Blood 85: 2093–2100.

21. Camire RM, Kalafatis M, Cushman M, Tracy RP, Mann KG, et al. (1995) Plasma factor Va kinetics in vivo. Blood 85: 2093–2100.

22. Camire RM, Kalafatis M, Cushman M, Tracy RP, Mann KG, et al. (1995) Plasma factor Va kinetics in vivo. Blood 85: 2093–2100.

23. Camire RM, Kalafatis M, Cushman M, Tracy RP, Mann KG, et al. (1995) Plasma factor Va kinetics in vivo. Blood 85: 2093–2100.

24. Camire RM, Kalafatis M, Cushman M, Tracy RP, Mann KG, et al. (1995) Plasma factor Va kinetics in vivo. Blood 85: 2093–2100.

25. Camire RM, Kalafatis M, Cushman M, Tracy RP, Mann KG, et al. (1995) Plasma factor Va kinetics in vivo. Blood 85: 2093–2100.

26. Camire RM, Kalafatis M, Cushman M, Tracy RP, Mann KG, et al. (1995) Plasma factor Va kinetics in vivo. Blood 85: 2093–2100.

27. Camire RM, Kalafatis M, Cushman M, Tracy RP, Mann KG, et al. (1995) Plasma factor Va kinetics in vivo. Blood 85: 2093–2100.

28. Camire RM, Kalafatis M, Cushman M, Tracy RP, Mann KG, et al. (1995) Plasma factor Va kinetics in vivo. Blood 85: 2093–2100.

29. Camire RM, Kalafatis M, Cushman M, Tracy RP, Mann KG, et al. (1995) Plasma factor Va kinetics in vivo. Blood 85: 2093–2100.

30. Camire RM, Kalafatis M, Cushman M, Tracy RP, Mann KG, et al. (1995) Plasma factor Va kinetics in vivo. Blood 85: 2093–2100.

31. Camire RM, Kalafatis M, Cushman M, Tracy RP, Mann KG, et al. (1995) Plasma factor Va kinetics in vivo. Blood 85: 2093–2100.

32. Camire RM, Kalafatis M, Cushman M, Tracy RP, Mann KG, et al. (1995) Plasma factor Va kinetics in vivo. Blood 85: 2093–2100.

33. Camire RM, Kalafatis M, Cushman M, Tracy RP, Mann KG, et al. (1995) Plasma factor Va kinetics in vivo. Blood 85: 2093–2100.

34. Camire RM, Kalafatis M, Cushman M, Tracy RP, Mann KG, et al. (1995) Plasma factor Va kinetics in vivo. Blood 85: 2093–2100.

35. Camire RM, Kalafatis M, Cushman M, Tracy RP, Mann KG, et al. (1995) Plasma factor Va kinetics in vivo. Blood 85: 2093–2100.

36. Camire RM, Kalafatis M, Cushman M, Tracy RP, Mann KG, et al. (1995) Plasma factor Va kinetics in vivo. Blood 85: 2093–2100.
66. Holcomb JB, Wade CE, Michalek JE, Chissolm GB, Zarzabal LA, et al. (2008) Increased plasma and platelet to red blood cell ratios improves outcome in 466 massively transfused civilian trauma patients. Ann Surg 248: 447–458.

67. Mosnier LO, Zampolli A, Kerschen EJ, Schupbach RA, Banerjee Y, et al. (2009) Hyperantithrombotic, noncytoprotective Glu149Ala-activated protein C mutant. Blood 113: 5970–5978.

68. Joyce DE, Gelbert L, Ciaccia A, DeHoff R, Grinnell BW (2003) Gene expression profile of antithrombotic protein C defines new mechanisms modulating inflammation and apoptosis. J Biol Chem 276: 11198–11203.

69. Mosnier LO, Zlokovic BV, Griffin JH (2007) The cytoprotective protein C pathway. Blood 109: 3161–3172.

70. Espana F, Grauer A, Heeb MJ, Hanson SR, Harker LA, et al. (1991) In vivo and in vitro complexes of activated protein C with two inhibitors in baboons. Blood 77: 1754–1760.